Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Core Insights - Voyager Therapeutics is advancing two preclinical programs targeting tau for Alzheimer's disease treatment, specifically the tau silencing gene therapy VY1706 and the anti-tau antibody VY7523 [1][2] Group 1: VY1706 Tau Silencing Gene Therapy - A single intravenous (IV) administration of VY1706 resulted in a dose-dependent reduction of tau mRNA by 44% to 73% and tau protein by 27% to 55% in a non-human primate study, with effects sustained for up to three months [4] - The therapy demonstrated broad distribution across brain regions affected by Alzheimer's disease, including the hippocampus and frontal cortex, while liver targeting was reduced by approximately 30-fold compared to wild type AAV9 [4][8] - VY1706 is currently in Investigational New Drug (IND)-enabling studies, with an IND filing anticipated in 2026 [4][8] Group 2: VY7523 Anti-Tau Antibody - Preclinical data indicate that the murine version of VY7523 selectively binds to pathological tau tangles and effectively reduces tau spread in a P301S mouse model [5][9] - VY7523 has shown approximately 70% inhibition of pathological tau spread in preclinical studies and is currently being evaluated in a multiple ascending dose trial for early Alzheimer's disease patients [9] - Initial tau positron emission tomography (PET) imaging data for VY7523 is expected in the second half of 2026 [5][9] Group 3: Upcoming Events and Presentations - Voyager will present data on both therapies at the AD/PD™ 2025 conference in Vienna from April 1-5, 2025, and will host a live webcast on April 7, 2025, to recap key findings [1][7] - Dr. Toby Ferguson, Chief Medical Officer, will participate in two panels discussing anti-tau therapies and drug development challenges at the conference [6]